Search results for "Autologous transplant"

showing 10 items of 19 documents

Uterus transplantation in a non-human primate: long-term follow-up after autologous transplantation

2012

BACKGROUND Uterus transplantation (UTx) may provide the first available treatment for women affected by uterine infertility. The present study aimed to further develop a surgical technique for autologous UTx in a non-human primate species and to assess long-term function. METHODS Female baboons (n= 16) underwent autologous transplantation of the uterus with the Fallopian tubes and ovaries, performed with a previously published surgical technique (n= 6, Group 1) or using a modified technique (n= 10; Group 2). The uterine arteries were dissected to the proximal end of the anterior branch (Group 1) or the entire (Group 2) internal iliac artery, and the ovarian veins were dissected to the cross…

medicine.medical_specialtyUterusOvaryBreedingIliac ArteryTransplantation AutologousVeinsUreterPregnancymedicine.arteryUterus transplantationmedicineAnimalsAutologous transplantationFallopian TubesPregnancybusiness.industryOvaryUterusRehabilitationObstetrics and GynecologyArteriesmedicine.diseaseInternal iliac arteryMenstruationSurgeryTreatment Outcomemedicine.anatomical_structureReproductive MedicineFemaleRenal veinbusinessFollow-Up StudiesPapioHuman Reproduction
researchProduct

Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies: High-Dose Cyclophosphamide Versus Plerixafor. on Beha…

2016

Abstract Background. Peripheral blood stem cell (PBSC) collection prior to high dose chemotherapy for autologous transplantation (ASCT) is a standard of care, and an attractive alternative to the use of bone marrow cells, for transplantation in Multiple Myeloma (MM). The optimal methodology for mobilizing PBSC has yet to be defined, both G-CSF and GM-CSF can be used; although, the stimulatory effect may be more pronounced when given after high dose cyclophosphamide (usually administered at a dose of 1.5 to 6g/m2 IV for one to two days) and use of Plerixafor, a CXCR4 antagonist (Mozobil®). The latter 2 options are preferred, overall, in France. Indeed, it was shown that the most recent combi…

medicine.medical_specialtyMobilizationbusiness.industryPlerixaforImmunologyCell BiologyHematologymedicine.diseaseBiochemistrySurgeryTransplantationHigh dose chemotherapyHigh dose cyclophosphamidemedicineAutologous transplantationIntensive care medicinebusinessMultiple myelomaHematopoietic Stem Cell Mobilizationmedicine.drugBlood
researchProduct

The role of stem cell transplantation in follicular lymphoma.

2017

With the introduction of novel treatments paradigms to if or when to use transplantation strategies for patients with follicular lymphoma have changed substantially. Autologous transplantation has been intensively evaluated as consolidation after first induction treatment with positive effects, however the introduction of Rituximab led to comparable improvements and HDT has been moved to relapse treatment. In this indication HDT was frequently use already at first relapse, but now is dominantly used in patients with a highrisk profile, e.g. failure of response, early or multiply relapse and/or signs of transformation. The ideal place for allogeneic transplantation is even harder to define, …

Oncologymedicine.medical_specialtyAllogeneic transplantationSide effectClinical BiochemistryFollicular lymphomaTransplantation Autologous03 medical and health sciences0302 clinical medicineInternal medicinemedicineAutologous transplantationHumansIn patientPrecision MedicineLymphoma Follicularbusiness.industryHematopoietic Stem Cell Transplantationmedicine.diseaseTransplantationOncology030220 oncology & carcinogenesisRituximabStem cellbusinessRituximab030215 immunologymedicine.drugBest practiceresearch. Clinical haematology
researchProduct

Impact of different strategies of second-line stem cell harvest on the outcome of autologous transplantation in poor peripheral blood stem cell mobil…

2005

The optimal approach to obtain an adequate graft for transplantation in patients with poor peripheral blood stem cell (PBSC) mobilization remains unclear. We retrospectively assessed the impact of different strategies of second-line stem cell harvest on the transplantation outcome of patients who failed PBSC mobilization in our institution. Such patients were distributed into three groups: those who proceeded to steady-state bone marrow (BM) collection (group A, n = 34); those who underwent second PBSC mobilization (group B, n = 41); those in whom no further harvesting was carried out (group C, n = 30). PBSC harvest yielded significantly more CD34+ cells than BM collection. Autologous trans…

AdultMalemedicine.medical_specialtyAntigens CD34Bone Marrow CellsCell CountTransplantation AutologousInternal medicineGranulocyte Colony-Stimulating FactorMedicineAutologous transplantationHumansLeukapheresisHematopoietic Stem Cell MobilizationAgedBone Marrow TransplantationRetrospective StudiesTransplantationPeripheral Blood Stem Cell TransplantationHematologyBlood Cellsbusiness.industryHematologyLeukapheresisMiddle AgedHematopoietic Stem Cell MobilizationGranulocyte colony-stimulating factorSurgeryTransplantationmedicine.anatomical_structureTreatment OutcomeHematologic NeoplasmsFemaleBone marrowStem cellbusinessBone marrow transplantation
researchProduct

FIRST-LINE THERAPY OF T-CELL LYMPHOMA: ALLOGENEIC OR AUTOLOGOUS TRANSPLANTATION FOR CONSOLIDATION - FINAL RESULTS OF THE AATT STUDY

2019

OncologyCancer Researchmedicine.medical_specialtyConsolidation (soil)business.industryHematologyGeneral Medicinemedicine.disease03 medical and health sciences0302 clinical medicineFirst line therapyOncology030220 oncology & carcinogenesisInternal medicinemedicineT-cell lymphomaAutologous transplantationbusiness030215 immunologyHematological Oncology
researchProduct

Autologous Transplantation of In Vivo Purged PBSC in CML

2000

To determine the effectiveness of different methods for the detection of tumor cell contamination of collected peripheral stem cells, we performed a study on 39 chronic myelogenous leukemia (CML) patients who were consecutively treated at our department. Analyses of tumor cell contamination by fluorescence in situ hybridization (FISH), conventional cytogenetics, and polymerase chain reaction (PCR) showed marked differences in the percentage of evaluable results: Quantitative analysis of tumor cell contamination was feasible in 60 of 105 (57%) samples evaluated with the use of conventional cytogenetic analysis and in 105 of 107 (98%) samples analyzed by FISH. PCR was evaluable in all 85 samp…

OncologyCancer Researchmedicine.medical_specialtymedicine.diagnostic_testCytogeneticsLeukapheresisBiologymedicine.diseasePhiladelphia chromosomelaw.inventionlawInternal medicineImmunologyGeneticsmedicineAutologous transplantationStem cellMolecular BiologyPolymerase chain reactionChronic myelogenous leukemiaFluorescence in situ hybridizationCancer Genetics and Cytogenetics
researchProduct

Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature res…

2014

Summary Salvage therapy followed by high-dose therapy (HDT) remains a mainstay for patients with relapsed lymphoma, however no optimal regimen has been defined. Here we report on the results of R-DexaBEAM (rituximab, dexamethasone, carmustine, etoposide, cytarabine, melphalan) followed by HDT. Patients aged 18–65 years, Eastern Cooperative Oncology Group performance score 0–2, with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) were eligible. R-Dexa-BEAM was given for two cycles followed by stem cell mobilization and HDT. Primary endpoint of the trial was progression-free-survival (PFS). One hundred and three patients were included: aggressive NHL (aNHL): diffuse large B-cell lymphom…

OncologyMelphalanAdultMalemedicine.medical_specialtyLymphoma B-CellFollicular lymphomaSalvage therapyKaplan-Meier EstimateDexamethasoneDrug Administration ScheduleAntibodies Monoclonal Murine-DerivedYoung Adultimmune system diseasesRecurrencehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineAutologous transplantationHumansProspective StudiesMelphalanEtoposideAgedEtoposideSalvage TherapyDose-Response Relationship Drugbusiness.industryPatient SelectionRemission InductionCytarabineHematologyMiddle Agedmedicine.diseaseCarmustineHematopoietic Stem Cell MobilizationLymphomaSurgeryMantle cell lymphomaRituximabFemalebusinessRituximabmedicine.drugBritish journal of haematology
researchProduct

Survival of elderly patients with multiple myeloma-Effect of upfront autologous stem cell transplantation

2016

Abstract Background The aim of this study was to determine the value of upfront autologous transplantation (ASCT) in elderly patients (60–79 years) with myeloma. Methods We analysed relative survival (RS) of patients diagnosed in 1998–2011 and treated with ASCT within 12 months after diagnosis in Germany (n = 3591; German Registry of Stem Cell Transplantation) and compare RS with survival of myeloma patients diagnosed in the same years in Germany (n = 13,903; population-based German Cancer Registries). Results Utilisation of ASCT has increased rapidly between 2000–2002 and 2009–2011 (60–64years: 7.0–43.0%; 65–69 years: 6.6–23.7%; 70–79 years: 0.4–4.0%). Comparison of 5-year RS of patients f…

OncologyMaleCancer Researchmedicine.medical_specialtyPopulationMedizinImproved survivalTransplantation Autologous03 medical and health sciences0302 clinical medicineAutologous stem-cell transplantationInternal medicineGermanyMedicineAutologous transplantationHumanseducationMultiple myelomaAgedRetrospective Studieseducation.field_of_studyRelative survivalbusiness.industryCancerMiddle Agedmedicine.diseaseSurvival AnalysisTransplantationOncology030220 oncology & carcinogenesisFemalebusinessMultiple Myeloma030215 immunologyStem Cell Transplantation
researchProduct

Alteration of HSC Functions in Thalassemia

2015

Abstract Beta-thalassemia represents one of the most globally widespread monogenic disorders and is characterized by significantly reduced or absent synthesis of hemoglobin beta-chains. In its severe form the insufficient production of adult hemoglobin results in altered erythropoiesis, hemolytic anemia, bone marrow (BM) hematopoietic hyperplasia and splenomegaly often associated with extramedullary hematopoiesis, requiring regular blood transfusions and iron chelation treatment. Over the last two decades many progresses were made in the field of allogeneic bone marrow (BM) transplantation to definitively cure beta-thalassemia. In parallel, experimental autologous transplantation protocols …

Ineffective erythropoiesisThalassemiaImmunologyCell BiologyHematologyBiologymedicine.disease_causemedicine.diseaseBiochemistryTransplantationHaematopoiesismedicine.anatomical_structureImmunologymedicineErythropoiesisAutologous transplantationBone marrowStem cellBlood
researchProduct

Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: Results f…

2021

Abstract Background: Treatment regimens including a proteasome inhibitor, immunomodulating agent and a monoclonal antibody (moAb) play an emerging role in the treatment of newly-diagnosed multiple myeloma (NDMM). This multicenter phase III trial of the German-speaking Myeloma Multicenter Group (GMMG HD6) investigated the addition of the anti-SLAMF7 moAb elotuzumab to lenalidomide / bortezomib / dexamethasone (RVd) in induction and consolidation therapy as well as to lenalidomide maintenance treatment in transplant-eligible NDMM. Patients and Methods: Patients were equally randomized into four treatment arms, stratified by International Staging System (ISS). Treatment consisted of four 21-da…

Oncologymedicine.medical_specialtybusiness.industryImmunologyCell BiologyHematologyNewly diagnosedmedicine.diseaseBiochemistryInternal medicineMedicineAutologous transplantationElotuzumabbusinessMultiple myelomaBortezomib/dexamethasonemedicine.drugLenalidomideBlood
researchProduct